Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Table 1 Demographic and clinical characteristics of patients

	Total N(748)	4 mg N(226)	8 mg N(509)	<65 yr. N(418)	≥65 yr. N(330)
Gender (woman), %	83.5	83.5	73.7^§	84.9	65.8^*
Age, mean (SD), yr	61.5(11.0)	61.2(11.1)	61.7(10.8)	53.9(8.1)	71.1(4.9)^*
BMI, mean (SD), Kg/m²	26.6(3.4)	26.5(3.7)	26.6(3.3)	26.0(3.5)	27.3(3.2)^*
OAB evolution time, mean (SD), d.	389.7(618.6)	405.6(695.7)	383.6(588.1)	316.5(388.6)	482.3(813.7)^*
OAB-V8 score (0–40)	17.6(7.1)	17.4(7.4)	17.6(7.0)	17.4(7.1)	17.8(7.1)
Concomitant conditions, %		69.8	66.4	59.0	77.9^*
Obesity (BMI ≥ 30 Kg/m²)	12.7	14.6	12.0	10.0	16.1^§
HBP	45.1	45.1	45.4	34.7	58.2^*
Urinary tract infections	19.7	18.1	20.0	21.3	17.6^§
DM	20.6	21.2	19.8	17.5	24.5^§
Depression	13.4	15.0	12.8	13.4	13.3
CVA	1.2	1.3	1.2	0.2	2.4^§
Parkinson’s	1.2	1.3	1.0	0.5	2.1
Concomitant medication, %	67.3	69.8	66.4	59.0	77.9^*

SD Standard deviation; BMI Body Mass Index; OAB (overactive bladder); HBP High blood pressure; DM Diabetes mellitus; CVA Cerebrovascular Accident*p between groups < 0.001; §p between groups < 0.05.

ISSN: 1471-2490